01 1Taro Pharmaceutical Industries
01 1IMIQUIMOD, USP (NEW ROS)
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-24
Pay. Date : 2024-03-01
DMF Number : 39004
Submission : 2024-03-31
Status : Active
Type : II
20
Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is IMIQUIMOD, USP (NEW ROS), with a corresponding US DMF Number 39004.
Remarkably, this DMF maintains an Active status since its submission on March 31, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 24, 2024, and payment made on March 01, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II
